Jonathan Repple

Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University Frankfurt, Frankfurt, Germany; Institute for Translational Psychiatry, University of Münster, Münster, Germany. Electronic address: repple@em.uni-frankfurt.de.

2 papers in the library · 11 citations · publishing 2025

Papers

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action

Biological Psychiatry March 8, 2025 Jonathan Repple, Maximilian Bayas, Chiara Möser et al. 8 citations

Rapid-acting antidepressants (RAADs) such as ketamine show promise for bipolar depression, but research remains limited compared to major depressive disorder. This review covers RAAD classes under investigation for bipolar depression, including NMDA antagonists (ketamine, esketamine, riluzole, felbamate), GABAA activators (zuranolone, pregnenolone, PEA), psychedelics (psilocybin, 5-MeO-DMT), muscarine receptor antagonists (scopolamine), and kappa opioid receptor antagonists (navacaprant). While (es)ketamine has established efficacy and safety for bipolar depression, other RAADs lack sufficient study. Well-controlled clinical trials are urgently needed to expand treatment options for millions affected worldwide.

DOI: 10.1016/j.biopsych.2025.02.903 Mdd #bipolardisorder manic depression Bipolar affective disorder #ketamine ketamine therapy +5

Effects of repeated intravenous esketamine administration on affective biases.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry January 1, 2025 Christine Reif-Leonhard, Shannon N Millard, Dorsa Ferdowssian et al. 3 citations

Repeated intravenous esketamine infusions improved emotion recognition for all emotions except sadness, where accuracy decreased, particularly for low-intensity expressions. Misclassifications of other emotions as sad also decreased, indicating a reduced response bias towards sadness. This shift emerged after the first infusion and consolidated over time. Participants showed significant reductions in feelings of sadness and irritability, and cognitive functioning improved. Among those receiving at least five infusions, 66.7% showed significant improvement. The findings suggest that esketamine's antidepressant effects may involve changes in emotion processing and cognition, with acute mood-lifting effects distinguishable from longer-lasting responses that consolidate after repeated administration.

DOI: 10.1080/15622975.2024.2441304 Full text Ema Rapid acting antidepressant Dosing Prediction +8